Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05935098 · ClinicalTrials.gov registry record · Phase 1
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
A Phase 1 study, sponsored by BeiGene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT05935098 is a Phase 1 study that was terminated before completion, run by BeiGene. The registered enrollment target is 99 participants.
The verdict
NCT05935098, a Phase 1 study, was terminated before completion, sponsored by BeiGene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
This study aims to evaluate how safe and well-tolerated the treatment is, how the body processes it, how it works on the tumors, and whether it shows early signs of fighting cancer in people with certain advanced or metastatic solid tumors. Key details of the study include: * The study is expected to last about 36 months. * Participants will receive treatment until they either no longer benefit from the treatment, experience side effects that are too severe, or choose to stop participating.
Interventions
- DRUG Tislelizumab
- DRUG Chemotherapy
- DRUG BGB-A3055
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2023-08-21 |
| Est. Completion | 2026-01-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05935098
The ClinicalTrials.gov registry entry for NCT05935098 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tislelizumab is the first listed.
NCT05935098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05935098 about?
NCT05935098 is a clinical study titled "BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors". This study aims to evaluate how safe and well-tolerated the treatment is, how the body processes it, how it works on the tumors, and whether it shows early signs of fighting cancer in people with certain advanced or metastatic solid tumors. Key details of the study include: * The study is expected...
What is the current status of trial NCT05935098?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2023-08-21. Estimated completion is 2026-01-27.
What interventions are being tested in trial NCT05935098?
The interventions under investigation include: Tislelizumab (DRUG), Chemotherapy (DRUG), BGB-A3055 (DRUG).
Who is sponsoring clinical trial NCT05935098?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.